Lilly makes fresh bet on IL-17 with $2.4B acquisition of Dice Therapeutics FDA puts Gilead's $225M BCMA CAR-T on hold over patient death, delaying potential rival to J&J, BMS AstraZeneca drops another GLP-1 after phase 1 data bust market-beating diabetes hopes Santhera, making good on its debts, offloads North American rights for DMD drug to Catalyst for up to $231M Bavarian Nordic bites back in chikungunya vaccine race, hitting phase 3 goal to stay on Valneva's heels FDA stalls F2G's plans to get first in new antifungal class to market More layoffs at Molecular Templates as biotech pays off debts to keep show on the road Bone Therapeutics' final asset buried after failure in phase 2 fracture study Beyond Air looks beyond lungs to target nitric oxide in autism Fierce Biotech M&A Tracker 2023: Lilly throws the Dice for $2.4B; Coherus claims new I-O assets with $65M Surface buy Fierce Biotech Fundraising Tracker '23: Attovia emerges with $60M; Beacon lights up with $120M Researchers set sights on commonly bought probiotic for dry eye disease potential | 